- Home
- PHAR vs BCX Comparison
PHAR vs BCX Comparison
Compare PHAR & BCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- BCX
- Stock Information
- Founded
- PHAR 1988
- BCX 2011
- Country
- PHAR Netherlands
- BCX United States
- Employees
- PHAR N/A
- BCX N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- BCX Finance/Investors Services
- Sector
- PHAR Health Care
- BCX Finance
- Exchange
- PHAR Nasdaq
- BCX Nasdaq
- Market Cap
- PHAR 718.1M
- BCX 725.6M
- IPO Year
- PHAR N/A
- BCX N/A
- Fundamental
- Price
- PHAR $10.45
- BCX $9.42
- Analyst Decision
- PHAR Strong Buy
- BCX
- Analyst Count
- PHAR 3
- BCX 0
- Target Price
- PHAR $30.00
- BCX N/A
- AVG Volume (30 Days)
- PHAR 2.6K
- BCX 370.6K
- Earning Date
- PHAR 07-31-2025
- BCX 01-01-0001
- Dividend Yield
- PHAR N/A
- BCX 6.99%
- EPS Growth
- PHAR N/A
- BCX N/A
- EPS
- PHAR N/A
- BCX N/A
- Revenue
- PHAR $320,708,000.00
- BCX N/A
- Revenue This Year
- PHAR $13.31
- BCX N/A
- Revenue Next Year
- PHAR $7.68
- BCX N/A
- P/E Ratio
- PHAR N/A
- BCX N/A
- Revenue Growth
- PHAR 24.13
- BCX N/A
- 52 Week Low
- PHAR $6.65
- BCX $8.25
- 52 Week High
- PHAR $12.61
- BCX $9.90
- Technical
- Relative Strength Index (RSI)
- PHAR 47.51
- BCX 54.85
- Support Level
- PHAR $10.41
- BCX $9.38
- Resistance Level
- PHAR $11.50
- BCX $9.54
- Average True Range (ATR)
- PHAR 0.32
- BCX 0.10
- MACD
- PHAR -0.17
- BCX -0.01
- Stochastic Oscillator
- PHAR 2.26
- BCX 46.97
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About BCX BlackRock Resources of Beneficial Interest
BlackRock Resources & Commodities Strategy Trust operates as an investment trust. Its investment objective is to seek high current income and current gains, with a secondary objective of capital appreciation. The company invests at least 80% of its total assets in equity securities issued by commodity or natural resources companies, derivatives with exposure to commodity or natural resources companies or investments in securities and derivatives linked to the underlying price movement of commodities or natural resources.